OCGN
Ocugen, Inc.
$1.21
-0.82%
$409.6M
No data for this timeframe.
Vol
Market Cap$409.6M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders50 funds
Inst. Value$115.3M
Inst. Activity11 buys / 2 sells
Reddit Sentiment80° Bullish
SEC Reports8
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001372299·Prev Close $1.22
Recent Activity
Jun 11, 2026
SEC
Ocugen filed an 8-K reporting results from its June 11, 2026 Annual Meeting and the formal appointment of Mohamed Genead
8-K — Impact 2/10
Jun 11, 2026
SEC
A small institutional cluster has formed in OCGN shares for Q4 2025, with five funds (led by State Street, RenTech, and
INST-CLUSTER — Impact 4/10
May 5, 2026
SEC
Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrangement revenue of $1.5
8-K — Impact 6/10
Apr 1, 2026
Insider
Zhang Junge acquired via exercise 15,000 shares
Director @ $0.5100 ($7.7K)
Inst.
STATE STREET CORP — DOUBLED
9,670,191 shares ($17.5M)
Inst.
MARSHALL WACE, LLP — DOUBLED
8,052,350 shares ($14.6M)
Jun 10, 2026
short_volume
Short Volume: OCGN — 56.6% short (1.5M / 2.6M)
Short: 1,466,847 | Exempt: 3,384 | TRF Vol: 2,590,553 | Short Ratio: 56.6% | Off-exchange volume (da
May 5, 2026
Press
Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a 90% discount to par, with net proceeds of ~$99.5M ($
Impact 7/10
Price Targets
$11.43
+844.5% upside
Strong Buy
Current $1.21
Low $7.00
Median $10.00
High $22.00
7 analysts
$7.00
$22.00
Analyst Ratings
3Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Canaccord Genuity | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Mar 17, 2026 | Canaccord Genuity | INITIATE | Buy |
| Mar 11, 2026 | Oppenheimer | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 ▼ -3.2% | $-0.06 — $-0.04 | -7% YoY | 6 |
| Next Q | $-0.05 | $-0.06 — $-0.04 | 24% YoY | 6 |
| Current FY | $-0.22 ▼ -3.9% | $-0.25 — $-0.18 | 3% YoY | 6 |
| Next FY | $-0.23 ▼ -634.1% | $-0.26 — $-0.18 | -5% YoY | 4 |
Latest Reports
NEUTRAL
8-K
2/10
Ocugen filed an 8-K reporting results from its June 11, 2026 Annual Meeting and the formal appointment of Mohamed Genead
Jun 11, 2026
BULLISH
INST-CLUSTER
4/10
A small institutional cluster has formed in OCGN shares for Q4 2025, with five funds (led by State Street, RenTech, and
Jun 11, 2026
BEARISH
Press
7/10
Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a 90% discount to par, with net proceeds of ~$99.5M ($
May 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $25.0M | — |
| STATE STREET CORP | $17.5M | DOUBLED |
| MARSHALL WACE, LLP | $14.6M | DOUBLED |
| BlackRock, Inc. | $13.2M | ADD |
| RTW INVESTMENTS, LP | $12.1M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 1, 2026 | Zhang Junge | M | $7.7K |
Reddit Sentiment
80°
Bullish
Bearish
Neutral
Bullish
50 institutional holders with $115.3M total value (63,692,558 shares) as of 2026-Q1. Top holders: VANGUARD, STATE, MARSHALL. Net buying activity: 11 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 13,804,111 | $25.0M | 21.7% | — |
| 2 | STATE STREET CORP | 9,670,191 | $17.5M | 15.2% | DOUBLED +143.0% |
| 3 | MARSHALL WACE, LLP | 8,052,350 | $14.6M | 12.6% | DOUBLED +218.2% |
| 4 | BlackRock, Inc. | 7,304,979 | $13.2M | 11.5% | ADD +60.3% |
| 5 | RTW INVESTMENTS, LP | 6,666,666 | $12.1M | 10.5% | NEW |
| 6 | CITADEL ADVISORS LLC | 2,809,157 | $5.1M | 4.4% | DOUBLED +160.5% |
| 7 | TWO SIGMA INVESTMENTS, LP | 2,251,282 | $4.1M | 3.5% | DOUBLED +828.4% |
| 8 | VANGUARD FIDUCIARY TRUST CO | 2,001,103 | $3.6M | 3.1% | — |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,275,600 | $2.3M | 2.0% | — |
| 10 | BANK OF AMERICA CORP /DE/ | 1,174,180 | $2.1M | 1.8% | DOUBLED +1090.0% |
| 11 | GOLDMAN SACHS GROUP INC | 1,127,406 | $2.0M | 1.8% | — |
| 12 | VANGUARD PORTFOLIO MANAGEMENT LLC | 935,799 | $1.7M | 1.5% | — |
| 13 | Point72 Asset Management, L.P. | 834,490 | $1.5M | 1.3% | ADD +95.8% |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 769,549 | $1.4M | 1.2% | — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 765,500 | $1.4M | 1.2% | — |
| 16 | MORGAN STANLEY | 677,906 | $1.2M | 1.1% | ADD +46.3% |
| 17 | Brevan Howard Capital Management LP | 448,162 | $811.2K | 0.7% | — |
| 18 | CITADEL ADVISORS LLC | 314,300 | $568.9K | 0.5% | DOUBLED +160.5% |
| 19 | Rafferty Asset Management, LLC | 282,902 | $512.1K | 0.4% | — |
| 20 | Jain Global LLC | 278,590 | $504.2K | 0.4% | DOUBLED +142.9% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | DOUBLED | 3,978,738 | 9,670,191 | +143.0% | $17.5M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 2,530,956 | 8,052,350 | +218.2% | $14.6M | 2026-Q1 |
| BlackRock, Inc. | ADD | 4,556,544 | 7,304,979 | +60.3% | $13.2M | 2026-Q1 |
| RTW INVESTMENTS, LP | NEW | — | 6,666,666 | — | $12.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 98,672 | 1,174,180 | +1090.0% | $2.1M | 2026-Q1 |
| Point72 Asset Management, L.P. | ADD | 426,293 | 834,490 | +95.8% | $1.5M | 2026-Q1 |
| MORGAN STANLEY | ADD | 463,454 | 677,906 | +46.3% | $1.2M | 2026-Q1 |
| Jain Global LLC | DOUBLED | 114,690 | 278,590 | +142.9% | $504.2K | 2026-Q1 |
| GROUP ONE TRADING LLC | ADD | 118,307 | 217,977 | +84.2% | $394.5K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 331,300 | 96,500 | -70.9% | $174.7K | 2026-Q1 |
| Mariner, LLC | ADD | 22,274 | 29,716 | +33.4% | $53.8K | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 114,979 | 26,365 | -77.1% | $47.7K | 2026-Q1 |
| CWM, LLC | ADD | 2,503 | 4,699 | +87.7% | $8.5K | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 1,355,377 | 3,978,738 | +193.6% | $5.4M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 290,200 | 1,700,400 | +485.9% | $2.3M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 73,088 | 678,547 | +828.4% | $916.0K | 2025-Q4 |
| MORGAN STANLEY | ADD | 290,564 | 463,454 | +59.5% | $625.7K | 2025-Q4 |
| GROUP ONE TRADING LLC | ADD | 68,098 | 118,307 | +73.7% | $159.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 154,372 | 98,672 | -36.1% | $133.2K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1,070 | 4,001 | +273.9% | $5.4K | 2025-Q4 |
| BlackRock, Inc. | TRIM | 5,590,930 | 4,054,458 | -27.5% | $6.6M | 2025-Q3 |
| CITADEL ADVISORS LLC | DOUBLED | 602,014 | 1,568,211 | +160.5% | $2.6M | 2025-Q3 |
| UBS Group AG | ADD | 654,379 | 1,024,879 | +56.6% | $1.7M | 2025-Q3 |
| BARCLAYS PLC | DOUBLED | 60,400 | 581,087 | +862.1% | $576.6K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 611,698 | 290,564 | -52.5% | $473.6K | 2025-Q3 |
1 unique insiders with 1 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Apr 1, 2026 | Zhang Junge | Director | EXERCISE | 15,000 | $0.5100 | $7.7K |
8 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 5 mixed, 2 neutral. Avg impact: 4.8/10.
NEUTRAL
8-K
2/10
Ocugen filed an 8-K reporting results from its June 11, 2026 Annual Meeting and the formal appointme
Jun 11, 2026
BULLISH
INST-CLUSTER
4/10
A small institutional cluster has formed in OCGN shares for Q4 2025, with five funds (led by State S
Jun 11, 2026
MIXED
8-K
6/10
Ocugen reported Q1 2026 GAAP EPS of -$0.06, missing consensus of -$0.05, while collaborative arrange
May 5, 2026
MIXED
PRESS-RELEASE
6/10
Ocugen reported Q1 2026 EPS of -$0.06, a 16.1% miss vs consensus of -$0.05, with revenue of $1.53M (
May 5, 2026
MIXED
8-K
6/10
Ocugen announced a private offering of $115M convertible senior notes due 2034 (plus $15M option), i
May 4, 2026
NEUTRAL
PRESS-RELEASE
2/10
Ocugen announced it will release Q1 2026 financial results on May 5, 2026, with a conference call. N
Apr 29, 2026
MIXED
8-K
6/10
Ocugen filed a petition in Delaware Court of Chancery seeking validation of a corporate action that
Mar 4, 2026
MIXED
8-K
6/10
Ocugen reported financial results for Q4 and full year 2025, showing increased R&D spending and net
Mar 4, 2026
BEARISH
7/10
Ocugen priced $115M of 6.75% convertible senior notes due 2034 at a 90% discount to par, with net pr
May 5, 2026
BULLISH
8/10
Ocugen announced positive 12-month Phase 2 data for OCU410, its gene therapy for geographic atrophy
Mar 24, 2026
MIXED
6/10
Ocugen reported Q4 and full-year 2025 financial results showing increased R&D spending and a wider n
Mar 4, 2026
BULLISH
8/10
Ocugen announced completion of patient enrollment in the Phase 3 liMeliGhT trial for its gene therap
Mar 2, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 3 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.43 mean target
+844.5% upside
Strong Buy (3.00)
$7.00 Low
$22.00 High
| Metric | Value |
|---|---|
| Current Price | $1.21 |
| Target Low | $7.00 |
| Target Mean | $11.43 |
| Target Median | $10.00 |
| Target High | $22.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.06 | $-0.04 | -6.7% | -3.2% | 2↑ 3↓ | $0.0B | -35.7% | 6 |
| Next Q 2026-09-30 |
$-0.05 | $-0.06 | $-0.04 | 23.8% | +0.0% | 2↑ 4↓ | $0.0B | -51.5% | 6 |
| Current FY 2026-12-31 |
$-0.22 | $-0.25 | $-0.18 | 2.9% | -3.9% | 2↑ 4↓ | $0.0B | -7.6% | 6 |
| Next FY 2027-12-31 |
$-0.23 | $-0.26 | $-0.18 | -5.2% | -634.1% | 1↑ 3↓ | $0.0B | 170.2% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.053 | |
| 7d ago | $-0.052 | -0.002 |
| 30d ago | $-0.052 | -0.002 |
| 60d ago | $-0.052 | -0.002 |
| 90d ago | $-0.057 | +0.003 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 17, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Mar 11, 2026 | Oppenheimer | INITIATE | — | Outperform |
| Mar 5, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 20, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
80°
Bullish
Bearish
Neutral
Bullish
6 mentions
6 bullish
0 bearish
5 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 13, 2026 | 2 | 67° Warm | 2 | 0 | 2 |
| Mar 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
thought on this ?
▲ 1
💬 1
⚡ 0.5
OCGN $30 - Oppenheimer Initiates Coverage
▲ 1
💬 1
⚡ 0.5
YOLO'ED Into OCGN ( Ocugen Inc ) & WON
▲ 1
💬 0
⚡ 0.5
YOLO'ED Into OCGN ( Ocugen, Inc ) & WON !!!
▲ 1
💬 0
⚡ 0.5
What’s your input?
▲ 1
💬 1
⚡ 0.5
Jun 10, 2026
short_volume
Short Volume: OCGN — 56.6% short (1.5M / 2.6M)
Short: 1,466,847 | Exempt: 3,384 | TRF Vol: 2,590,553 | Short Ratio: 56.6% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: OCGN — 56.5% short (0.9M / 1.6M)
Short: 901,290 | Exempt: 17,954 | TRF Vol: 1,595,081 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: OCGN — 60.3% short (1.5M / 2.5M)
Short: 1,520,186 | Exempt: 1,153 | TRF Vol: 2,519,459 | Short Ratio: 60.3% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: OCGN — 56.0% short (1.2M / 2.1M)
Short: 1,163,709 | Exempt: 4,312 | TRF Vol: 2,078,350 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
other
Ocugen to Participate in Upcoming June Investor and Industry Conferences
<p align="left">MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology lead
Jun 2, 2026
short_volume
Short Volume: OCGN — 60.8% short (1.4M / 2.3M)
Short: 1,400,986 | Exempt: 298 | TRF Vol: 2,303,410 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: OCGN — 65.1% short (1.9M / 2.9M)
Short: 1,868,639 | Exempt: 293,730 | TRF Vol: 2,869,498 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: OCGN — 83.0% short (8.1M / 9.8M)
Short: 8,127,839 | Exempt: 5,800 | TRF Vol: 9,791,827 | Short Ratio: 83.0% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: OCGN — 56.9% short (1.5M / 2.7M)
Short: 1,546,034 | Exempt: 69 | TRF Vol: 2,715,826 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: OCGN — 56.5% short (1.6M / 2.8M)
Short: 1,584,579 | Exempt: 756 | TRF Vol: 2,806,076 | Short Ratio: 56.5% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: OCGN — 61.5% short (1.3M / 2.1M)
Short: 1,285,947 | Exempt: 2,122 | TRF Vol: 2,092,201 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: OCGN — 57.2% short (1.5M / 2.7M)
Short: 1,541,587 | Exempt: 16 | TRF Vol: 2,693,135 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 14, 2026
other
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
Includes Full Exercise of $15.0 million Over-Allotment Option <pre>Includes Full Exercise of $15.0 million Over-Allotment Option</pre>
May 14, 2026
short_volume
Short Volume: OCGN — 58.1% short (1.4M / 2.4M)
Short: 1,394,953 | Exempt: 21,626 | TRF Vol: 2,402,065 | Short Ratio: 58.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
other
Ocugen to Participate in Upcoming May Scientific and Investor Conferences
<p>MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene the